Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility?

Nephron

Volumn 74, Issue 1, 1996, Pages 158-167

  Yamasaki, Fumiaki ^a   Ishibashi, Masaaki ^a   Nakakuki, Masanori ^a   Watanabe, Mitsutoshi ^a   Shinkawa, Tomoaki ^a   Mizota, Masahiro ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Cisplatin; Lysosomal fragility; Nephrotoxicity; Ulinastatin

Indexed keywords

CISPLATIN; LYSOSOME ENZYME; MALONALDEHYDE; N ACETYL BETA GLUCOSAMINIDASE; PLATINUM; ULINASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; ENZYME REPRESSION; EPITHELIUM CELL; HYALINE DEGENERATION; KIDNEY CORTEX SLICE; LYSOSOME; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; UREMIA;

EID: 0029740027     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189296     Document Type: Article

References (43)

1. Goldstein RS. Mayer GH: The nephrotoxicity of cisplatin (minircvicw). Life Sci 1983:32: 685-690.
2. Garnick MB. Mayer RJ. Abclson HT: Acute renal failure associated with cancer treatment; in Brenner BM. Lazarus JM (eds): Acute Renal Failure, cd2. New York. Churchill-Living-stonc, 1988. pp 621-657.
3. Wachtcr E. Hoehstrasscr K: Kunitz-type inhibitors derived by limited proteolysis of the inter-a-trypsin inhibitor. IV. The amino acid sequence of the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe Scvlcrs Z Physiol Chcm 1981:362:1351-1355.
4. Sumi H. Takada Y. Takada A: Studies on human urinary trypsin inhibitor. 1. Its modification on treatment of urine with acid. Thromb Res 1977:11:747-754.
5. Gebhard W, Hochstrasser K. Fritz H. Enghild JJ. Pizzo SV. Salvescn G: Structure of intcr-a-inhibitor (inter-a-trypsin inhibitor) and pre-a-inhibitor: Current state and proposition of a new terminology. Biol Chcm Hoppe Seyler 1990:371:13-22.,'
6. Gebhard W. Hochstrasser K: Inter-a-trypsin inhibitor and its close relatives: in Barrett AJ. Salvescn G (eds): Proteinase Inhibitors. Amsterdam, Elsevier. 1986, pp 389-401.
7. Toyoda H. Ikci T. Dcmachi Y, Toida T. Inta-nari T: Structural analysis of the N-linked oligosaccharides from human urinary trypsin inhibitor. Chem Pharm Bull 1992:40:2882-2884.
8. Toyoda H. Kobayashi S. Sakamoto S. Toida T. Imanari T: Structural analysis of a low-sulfated chondroitin sulfate chain in human urinary trypsin inhibitor. Biol Pharm Bull 1993:16: 945-947.
9. Bourguignon J. Diarra-Mehrpour M. Sesboüé R. Frain M. Salatrcpat JM. Martin, IP. Salicr JP: Human inter-a-trypsin inhibitor: Characterization and partial nucleotide sequencing of a light chain-encoding cDNA. Biochem Bio-phys Res Commun 1985; 131:1146-1153.
10. Kaumcvcr JF. Polazzi JO. Kotick MP: The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-a-trypsin inhibitor also encodes ai-microglobulin (protein HC). Nucleic Acids Res 1986;14:7839-7850.
11. Salier JP: Inter-a-trypsin inhibitor: Emergence of a family with the Kunitz-type protease inhibitor supcrfamily. Trends Biochem Sci 1990:15: 435-439.
12. Umeki S, Tsukiyama K. Okimoto N, Soejima R: Urinaslatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci 1989:298:221-226.
13. Ishigami M. Eguchi M. Yabuki S: Beneficial effects of the urinary trypsin inhibitor urinasta-tin on renal insults induced by gentamicin and mercuric chloride (HgCD) poisoning. Nephron 1991:58:300-305.
14. Kobayashi H. Ohi H. Terao T: Prevention by urinastatin of ra-diarnminedichloroplatinum-induced nephrotoxicity in rabbits: Comparison of urinary enzyme excretions and morphological alterations by electron microscopy. Asia Oceania J Obstet Gynaecol 1991;17:277-288.
15. Aggarwal SK. Whitchousc MW, Ramachan-dran C: Ultrastructural cITccts of cisplatin; in Prestayko AW, Crooke ST. Carter SK (eds): Cisplatin-Current Status and New Development. New York, Academic Press. 1980, pp 79-111.
16. McGuinncss JE. Proctor PH, Demopoulos HB. Hokanson JA. Kirkpatrick DS: Amelioration of cisplatin nephrotoxicity by orgotein (superoxide dismutase). Physiol Chcm Phys 1987:10: 267-277.
17. Sugihara K. Nakano S. Koda M. Tanaka K. Fukuishi N. Gemba M: Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jpn J Pharmacol 1987:43:247-252.
18. Hull RN. Cherry WR. Weaver GW: The origin and characteristics of a pig kidney cell strain. LLC-PK,. In Vitro 1976:12:670-677.
19. Pera MF Jr. Harder IIC: Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chcm 1977;23: 1245-1249.
20. Wrdblewski F. La Due JS: Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955:50:210-213.
21. Kameyama Y. Gemba M: The iron chelator deferoxamine prevents cisplatin-induced lipid peroxidation in rat kidney cortical slices. Jpn J Pharmacol 1991;57:259-262.
22. Buegc JA. Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978:52:302-310.
23. Sedlak J. Lindsay RH: Estimation of total, protein-bound. and nonprotcin sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968:25:192-205.
24. Pera MF Jr. Zook BC. Harder HC: Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological deposition of cis-dichlorodiammineplatinum ID in rats. Cancer Res 1979;39:1269-1277.
25. Dobvan DC. Bull JM. Strebcl FR. Sunderland BA. Bulger RE: Protective effects of 0-(p-hydroxvcthyl)rutoside on cw-platinum-in-duccd acute renal failure in the rat. Lab Invest 1986:55:557-563.
26. Deray G. Dubois M. Beaufils H. Cacoub P. Anouar M. Jaudon MC. Baumclou A. Jouan-ncau C. Jacobs C: Effects of nifedipine in cis-platinum-induced nephrotoxicity in rats. Clin Nephrol 1988:30:146-150.
27. Heyman SN. Rosen S, Silva P. Spokes K. Ego-rin MJ. Epstein FH: Protective action of glycine in cisplatin nephrotoxicity. Kidney Int 1991:40:273-279.
28. Ishikawa M. Takayanagi Y. Sakai K: The deleterious effect of buthioninc sulfoximinc. a glutathione-depleting agent, on the cisplatin toxicity in mice. Jpn J Pharmacol 1990:52:652-655.
29. Choic DD. Longnccker DS. Del Campo AA: Acute and chronic cisplatin nephrotoxicity in rats. Lab Invest 1981:44:397-402.
30. Chopra S, Kaufman JS. Jones TW, Hong WK. Gchr MK, Hamburger RJ. Flamenbaum W, Trump BF: O., v-diamminedichloroplalinum-induced acute renal failure in the rat. Kidncv Int 1982;21:54-64.
31. Safirstein R. Miller P. Dikman S. Lyman N. Shapiro C: Cisplalin nephrotoxicity in rats: Defect in papillary hypertonicity. Am J Physiol 1981:241:F175-F185.
32. Ward JM. Fauvic KA: The nephrotoxic effects of m-dichlorodiammine-platinum (11) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 1976:38:535-547.
33. Jones TW. Chopra S. Kaufman JS. Flamenbaum W. Trump BF: C'li-diammincdichloro-platinum ID-induccd acute renal failure in the rat. Lab Invest 1985:52:363-374.
34. Itoh H. Ide H, Kataoka H. Tomita M. Yoshiha-ra H. Nawa Y: cDNA sequencing of mouse cq-microglobulin inter-a-trypsin inhibitor light chain and its expression in acute inflammation. J Biochem 1994:116:767-772.
35. Ohzawa T. Takahashi Y. Tsuchiya T. Ogihara T. Nakai Y, Kohda K, Tanaka S. Ishiguro J: Studies on the metabolic fate of ulinastatin. I. Pharmacokinetics in rats. mice, and rabbits following a single intravenous dose (English abstract). Xcnobiotic Mclab Deposit 1990:5: 739-753.
36. Takeuchi S. Suzuki T. Shiba T. Urita U, Mura-kuni H: Clinical experience of MR-20 on pancreatitis and its plasma concentration in healthy volunteers (Japanese). Jpn J Clin Exp 1985:62:626-630.
37. Nishijima J. Hiraoka N, Murata A, Oka Y. Kitagawa K. Tanaka N. Toda H. Mori T: Pro-tease inhibitors (gabcxate mesylate and ulinastatin) stimulate intracellular chemilumines-cence in human neutrophils. J Leukoc Biol 1992:52:262-268.
38. Sadzuka Y. Shoji T. Takino Y: Change in lipid peroxide levels in rat tissues after cisplalin administration. Toxicol Lett 1991:57:159-166.
39. Bompart G: Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. Toxicol Lett 1989:48:193-199.
40. Sadzuka Y. Shoji T. Takino Y: Effect of cispla-tin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992;43:1872-1875.
41. Sadzuka Y, Shoji T. Takino Y: Mechanism of the increase in lipid peroxide induced by cisplalin in the kidneys of rats. Toxicol Lett 1992; 62:293-300.
42. Nakahama H. Nakanishi T. Sugita M: Cvto-protcctivc effects of ulinastatin against hypoxic injury' to LLC-PK1 cells. Nephron 1994:68: 411-412.
43. Oda T. Miyawaki T. Sameshima T. Miyao J: Antishock elTccts of urinary trypsin inhibitor. MR-20 (English abstract). Jpn J Anesthesiol 1984:33:137-142.